Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
2
institutions
Market cap
$24.8B
70M shares
52-week range
$223.83 – $386.00
77% from low
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Exchange
NYSE
CS
West Pharmaceutical Services is based in Pennsylvania and is a key supplier to firms in the pharmaceutical, biotechnology, and generic drug industries. West sells elastomer-based packaging components (including stoppers, seals, and plungers), nonglass containment solutions, and auto-injectors for injectable drugs, which include large-molecule biologics, peptides such as GLP-1 receptor agonists, and small-molecule drugs. The company reports in two segments: proprietary products (about 80% of total revenue) and contract-manufactured products (about 20% of total revenue). It generates approximately 55% of its revenue from international markets and 45% from the United States.
www.westpharma.comNo one on the platform currently holds WST.
| Institution | Shares | Reported |
|---|---|---|
| Renaissance Technologiesas of 2026-03-31 | 209,660 | $52.5M |
| Bridgewater Associatesas of 2026-03-31 | 23,161 | $5.8M |
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-07-29 | $0.2200 | 2026-08-05 |
| 2026-04-29 | $0.2200 | 2026-05-06 |
| 2026-01-28 | $0.2200 | 2026-02-04 |
| 2025-11-12 | $0.2200 | 2025-11-19 |
| 2025-07-30 | $0.2100 | 2025-08-06 |
| 2025-04-30 | $0.2100 | 2025-05-07 |
| 2025-02-07 | $0.2100 | 2025-02-11 |
| 2024-11-13 | $0.2100 | 2024-11-20 |
| 2024-07-31 | $0.2000 | 2024-08-07 |
| 2024-04-23 | $0.2000 | 2024-05-01 |
No one on the platform has traded WST yet.
| 2024-01-30 | $0.2000 | 2024-02-07 |
| 2023-11-07 | $0.2000 | 2023-11-15 |
| Execution date | Ratio |
|---|---|
| 2013-09-27 | 2-for-1 |
Click to see transaction details on SEC.gov. Form 4s cover trades by officers, directors, and 10%+ owners, due within 2 business days of the trade.
Fundamental analysis of $WST (WEST PHARMACEUTICAL SERVICES INC) based on financial data and reported results. #WST #WEST
View on StockTwits ↗$WST Supplies components used in injectable diabetes and obesity drugs, one of the fastest-growing segments in healthcare. Demand from GLP-1 therapies has been a major driver of recent Growth…
View on StockTwits ↗$WST Opportunity Deutsche Bank raises target price to $420 from $405
View on StockTwits ↗https://www.marketbeat.com/earnings/reports/2026-7-23-west-pharmaceutical-services-inc-stock/ $WST West Pharmaceutical Services Earnings T
View on StockTwits ↗$CLF $WST $DGX $RTX $LMT PRE-MARKET MOVERS: Currently Higher After Earnings: - Cleveland-Cliffs (CLF) up 11.3% - West Pharmaceuticals (WST) up 8.8% - Quest Diagnostics (DGX) up 7.6% - RTX (RTX) up 5.7% - Lockheed Martin (LMT) up 5.3% - Thermo Fisher (TMO) up 6.2% - Tractor Supply (TSCO) up 3.0% - McCormick (MKC) up 0.6% - Dow Inc. (DOW) up 0.2% Currently Lower After Earnings: - Alphabet (GOOGL) down 5.5% - STMicroelectronics (STM) down 17.4% - Tesla (TSLA) down 8.1% - American Airlines (AAL) down 5.8% - Infosys (INFY) down 5.3% - T-Mobile (TMUS) down 6.3% - Huntington Bancshares (HBAN) down 2.6% - Harley-Davidson (HOG) down 3.5%
View on StockTwits ↗$WST Q2 '26 Earnings Results & Recap • Reported GAAP EPS of $2.17 up 19.23% YoY • Reported revenue of $872.3M up 13.80% YoY • West Pharmaceutical Services, Inc. expects full-year 2026 net sales of $3.345 billion to $3.380 billion and adjusted-diluted EPS of $8.85 to $9.05, while third-quarter 2026 adjusted-diluted EPS is $2.14 to $2.24.
View on StockTwits ↗$WST reported - EPS and - revenue for Q2. http://www.estimize.com/intro/wst?chart=historical&metric_name=eps&utm_content=WST&utm_medium=act
View on StockTwits ↗The 2026 Dividend Champions: Updates, Performance, and Analysis - Updated 07/10/26 https://www.dividendpower.org/2026-dividend-champions/ $BKUT $RNR $KO $SYK $WST
View on StockTwits ↗The most recent Dark Pools signal on $WST triggered on 2026-07-06. The expected return for the selected horizon is +12.67% with a historical profit probability of +65.52%. Learn more: https://axlfi.com/factor-analysis?symbol=WST&factor=dark_pools&timeframe=daily
View on StockTwits ↗sld some winners (partial) to take profits. sld $EW for a 10% gain; sld $MNST for a 120% gain; sld $MSM for a 45% gain; sld $WST for a 20% gain;
View on StockTwits ↗Final Trade: WST, URI, SMH, MCD $wst $uri $smh $mcd https://www.cnbc.com/video/2026/06/09/final-trade-wst-uri-smh-mcd.html?__source=iosappshare%7Ccom.stocktwits.StockTwits.STShareExtension
View on StockTwits ↗$WST Current Stock Price: $310.67 Contracts to trade: $310.0 WST Jun 18 2026 Call Entry: $10.10 Exit: $12.97 ROI: 28% Hold ~30 days Shared as daily free alerts and for educational purposes only. https://dailypickai.com/freealerts
View on StockTwits ↗$NSI $MPWR $MSGS $WST I told you last week - Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe 2026 SYMBOL(MX) Magnachip a small cap power solutions semiconductor company based in South Korea. • MKT Cap of $230 million. • Revenue of $180 million. • 8 inch foundry worth approximately 200 million – 36K wafers a month • Cash of $50 million, trading at $5.70 a share. (as of last Friday) • Won’t be at this price for long. Magnachip to Showcase MV MOSFET Portfolio for AI Servers and Data Centers Alongside Its Broader Power Semiconductor Portfolio at PCIM Europe https://www.businesswire.com/news/home/20260526332549/en/Magnachip-to-Showcase-MV-MOSFET-Portfolio-for-AI-Servers-and-Data-Centers-Alongside-Its-Broader-Power-Semiconductor-Portfolio-at-PCIM-Europe-2026
View on StockTwits ↗$WST Great piece that accurately captures WST's current position. So if you want to refresh your understanding of WST or learn about WST for the first time, this is essential reading. https://everyticker.com/quote/WST/analysis/three-tailwinds-converge-why-west-pharmaceutical-s-margin-expansion-is-just-beginning-nyse-wst
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2026 | $3.4B | +10.0% | $8.94 | $8.56–$9.06 | 39.1× | 10 |
| 2027 | $3.6B | +6.2% | $9.95 | $9.32–$10.18 | 35.1× | 10 |
| 2028 | $3.8B | +7.1% | $11.29 | $10.28–$12.43 | 30.9× | 5 |
| 2029 | $4.2B | +9.3% | $12.97 | $12.60–$13.29 | 26.9× | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 8 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-07-23 | $2.08 | $2.37 | +13.9% |
| 2026-04-23 | $1.68 | $2.13 | +26.8% |
| 2026-02-12 | $1.83 | $2.04 | +11.5% |
| 2025-10-23 | $1.68 | $1.96 | +16.7% |
| 2025-07-24 | $1.51 | $1.84 | +21.9% |
| 2025-04-24 | $1.22 | $1.45 | +18.9% |
| 2025-02-13 | $1.71 | $1.82 | +6.4% |
| 2024-10-24 | $1.50 |
| $1.85 |
| +23.3% |
| $28.9B |
| — |
| INCYIncyte Corporation | $120.16 | -0.30% | $24.4B | — |
| LHLabcorp Holdings Inc. | $318.13 | -1.38% | $26.1B | — |
Source: Financial Modeling Prep · peers by sector/industry